Literature DB >> 12543373

Critical review of acylation-stimulating protein physiology in humans and rodents.

Katherine Cianflone1, Zhunan Xia, Lan Ying Chen.   

Abstract

In the last few years, there has been increasing interest in the physiological role of acylation-stimulating protein (ASP). Recent studies in rats and mice, in particular in C3 (-/-) mice that are ASP deficient, have advanced our understanding of the role of ASP. Of note, the background strain of the mice influences the phenotype of delayed postprandial triglyceride clearance in ASP-deficient mice. Administration of ASP in all types of lean and obese mice studied to date, however, enhances postprandial triglyceride clearance. On the other hand, regardless of the background strain, ASP-deficient mice demonstrate reduced body weight, reduced leptin and reduced adipose tissue mass, suggesting that ASP deficiency results in protection against development of obesity. In humans, a number of studies have examined the relationship between ASP, obesity, diabetes and dyslipidemia as well as the influence of diet, exercise and pharmacological therapy. While many of these studies have small subject numbers, interesting observations may help us to better understand the parameters that may influence ASP production and ASP action. The aim of the present review is to provide a comprehensive overview of the recent literature on ASP, with particular emphasis on those studies carried out in rodents and humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543373     DOI: 10.1016/s0005-2736(02)00686-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  80 in total

1.  The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Talat H Malik; Andrea Cortini; Daniele Carassiti; Joseph J Boyle; Dorian O Haskard; Marina Botto
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

Review 2.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

Review 3.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

4.  C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.

Authors:  Mohamed Jalloul Nsaiba; Marc Lapointe; Hajer Mabrouk; Wahiba Douki; Lotfi Gaha; Louis Pérusse; Claude Bouchard; Besma Bel Hadj Jrad; Katherine Cianflone
Journal:  Neurochem Res       Date:  2015-02-27       Impact factor: 3.996

Review 5.  Treatment of fibrosis in nonalcoholic fatty liver disease.

Authors:  Maarouf A Hoteit; Frank A Anania
Journal:  Curr Gastroenterol Rep       Date:  2007-03

Review 6.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 7.  Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training.

Authors:  Christian K Roberts; Andrea L Hevener; R James Barnard
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

8.  Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels.

Authors:  Sabina Paglialunga; Pierre Julien; Youssef Tahiri; Francois Cadelis; Jean Bergeron; Daniel Gaudet; Katherine Cianflone
Journal:  J Lipid Res       Date:  2009-02-23       Impact factor: 5.922

Review 9.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 10.  The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?

Authors:  Luca Valenti; Anna Ludovica Fracanzani; Silvia Fargion
Journal:  Semin Immunopathol       Date:  2009-05-14       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.